Injectable Weight Management Medications
GLP-1 Medication Comparison
(Injectables)
Medication | Type | Cost | Avg Weight Loss*** | How It Works | Dosing | Common Side Effects |
---|---|---|---|---|---|---|
Semaglutide (Wegovy®) | GLP-1 agonist | $$$ | 15% | Mimics GLP-1 hormone to reduce appetite and slow digestion | Weekly | Nausea, diarrhea, constipation |
Semaglutide (Ozempic®) | GLP-1 agonist | $$$ | 15% | Mimics GLP-1 hormone to regulate blood sugar and reduce appetite | Weekly | Nausea, vomiting, diarrhea |
Liraglutide (Saxenda®) | GLP-1 agonist | $$$ | 10% | Activates GLP-1 receptors to increase fullness and reduce hunger | Daily | Nausea, headache, dizziness |
Tirzepatide (Zepbound®) | GLP-1/GIP agonist | $$ | 20% | Dual-action: targets both GLP-1 and GIP receptors for enhanced appetite suppression | Weekly | Nausea, diarrhea, constipation |
Tirzepatide (Mounjaro®) | GLP-1/GIP agonist | $$$ | 20% | Dual-action: targets both GLP-1 and GIP receptors for blood sugar control and weight loss | Weekly | Nausea, vomiting, diarrhea |
Compounded Semaglutide** | GLP-1 agonist | $ | 15% | Same mechanism as branded semaglutide (not FDA-evaluated) | Weekly | Similar to branded (varies by pharmacy) |
Compounded Tirzepatide** | GLP-1/GIP agonist | $ | 20% | Same mechanism as branded tirzepatide (not FDA-evaluated) | Weekly | Similar to branded (varies by pharmacy) |
This chart provides general information. Well Brain Body clinicians will help determine which option may be appropriate for your individual needs.
Compounded Medications
These are customized formulations prepared by licensed pharmacies to meet specific patient needs under a provider's supervision. They're created in:
503A Pharmacies: Prepare medications for individual patients
503B Facilities: Produce larger batches of sterile compounds
*Includes membership only. Medication cost extra. **Disclaimer: Compounded medications haven't undergone FDA approval. Their safety and effectiveness may differ from commercial drugs. Well Brain Body partners only with accredited U.S. compounding pharmacies meeting rigorous standards. ***In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) and Zepbound (15 mg) in patients without diabetes and with BMI ≥30, or BMI ≥27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone.